FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783608772> ?p ?o ?g. }

• W2783608772 endingPage "679" @default.
• W2783608772 startingPage "666" @default.
• W2783608772 abstract "Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib." @default.
• W2783608772 created "2018-01-26" @default.
• W2783608772 creator A5015131529 @default.
• W2783608772 creator A5019866348 @default.
• W2783608772 creator A5047631289 @default.
• W2783608772 creator A5054008156 @default.
• W2783608772 creator A5056554686 @default.
• W2783608772 creator A5067154165 @default.
• W2783608772 creator A5082635493 @default.
• W2783608772 creator A5090615083 @default.
• W2783608772 date "2018-01-09" @default.
• W2783608772 modified "2023-10-13" @default.
• W2783608772 title "Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice" @default.
• W2783608772 cites W1565211228 @default.
• W2783608772 cites W1567332472 @default.
• W2783608772 cites W1819620602 @default.
• W2783608772 cites W1874872148 @default.
• W2783608772 cites W1891620832 @default.
• W2783608772 cites W1969953749 @default.
• W2783608772 cites W1984412456 @default.
• W2783608772 cites W1986924929 @default.
• W2783608772 cites W1998407948 @default.
• W2783608772 cites W1999128869 @default.
• W2783608772 cites W2011950935 @default.
• W2783608772 cites W2025707347 @default.
• W2783608772 cites W2026848004 @default.
• W2783608772 cites W2039003817 @default.
• W2783608772 cites W2054220445 @default.
• W2783608772 cites W2071549499 @default.
• W2783608772 cites W2076804009 @default.
• W2783608772 cites W2108206643 @default.
• W2783608772 cites W2115709245 @default.
• W2783608772 cites W2151074096 @default.
• W2783608772 cites W2157799317 @default.
• W2783608772 cites W2163690533 @default.
• W2783608772 cites W2171771895 @default.
• W2783608772 cites W2187899653 @default.
• W2783608772 cites W2190884983 @default.
• W2783608772 cites W2191219754 @default.
• W2783608772 cites W2233614027 @default.
• W2783608772 cites W2270313998 @default.
• W2783608772 cites W2307952155 @default.
• W2783608772 cites W2399623634 @default.
• W2783608772 cites W2474112571 @default.
• W2783608772 cites W2506185426 @default.
• W2783608772 cites W2512668867 @default.
• W2783608772 cites W2519500141 @default.
• W2783608772 cites W2547585100 @default.
• W2783608772 cites W2548089616 @default.
• W2783608772 cites W2548268469 @default.
• W2783608772 cites W2549814215 @default.
• W2783608772 cites W2550091596 @default.
• W2783608772 cites W2557801192 @default.
• W2783608772 cites W2558394416 @default.
• W2783608772 cites W2566053885 @default.
• W2783608772 cites W2575189453 @default.
• W2783608772 cites W2580500393 @default.
• W2783608772 cites W2580953357 @default.
• W2783608772 cites W2587295203 @default.
• W2783608772 cites W2587387808 @default.
• W2783608772 cites W2592488972 @default.
• W2783608772 cites W2594599490 @default.
• W2783608772 cites W2602079691 @default.
• W2783608772 cites W2604832096 @default.
• W2783608772 cites W2605411035 @default.
• W2783608772 cites W2606995900 @default.
• W2783608772 cites W2607033541 @default.
• W2783608772 cites W2610114488 @default.
• W2783608772 cites W2613723809 @default.
• W2783608772 cites W2614325329 @default.
• W2783608772 cites W2739393823 @default.
• W2783608772 cites W3049379535 @default.
• W2783608772 cites W4245178503 @default.
• W2783608772 cites W4248201686 @default.
• W2783608772 cites W981207258 @default.
• W2783608772 doi "https://doi.org/10.1111/bjh.15080" @default.
• W2783608772 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29318593" @default.
• W2783608772 hasPublicationYear "2018" @default.
• W2783608772 type Work @default.
• W2783608772 sameAs 2783608772 @default.
• W2783608772 citedByCount "44" @default.
• W2783608772 countsByYear W27836087722018 @default.
• W2783608772 countsByYear W27836087722019 @default.
• W2783608772 countsByYear W27836087722020 @default.
• W2783608772 countsByYear W27836087722021 @default.
• W2783608772 countsByYear W27836087722022 @default.
• W2783608772 countsByYear W27836087722023 @default.
• W2783608772 crossrefType "journal-article" @default.
• W2783608772 hasAuthorship W2783608772A5015131529 @default.
• W2783608772 hasAuthorship W2783608772A5019866348 @default.
• W2783608772 hasAuthorship W2783608772A5047631289 @default.
• W2783608772 hasAuthorship W2783608772A5054008156 @default.
• W2783608772 hasAuthorship W2783608772A5056554686 @default.
• W2783608772 hasAuthorship W2783608772A5067154165 @default.
• W2783608772 hasAuthorship W2783608772A5082635493 @default.
• W2783608772 hasAuthorship W2783608772A5090615083 @default.
• W2783608772 hasBestOaLocation W27836087721 @default.
• W2783608772 hasConcept C126322002 @default.

• next